'Advanced breast cancer' presentation slideshows

Endocrine resistance: molecular pathways and rational development of targeted therapies

1.08k views • 66 slides

Optimizing Treatment for HER2-Positive Advanced Breast Cancer

Optimizing Treatment for HER2-Positive Advanced Breast Cancer. Program Goals. CLEOPATRA Study Design. First-Line Therapy of HER2+ MBC. Therapy of MBC After Progression on First-Line Anti-HER2 Treatment. EMILIA: PFS. EMILIA: OS at Second Interim Analysis. EMILIA: Hematologic Adverse Events.

1.59k views • 52 slides

A Report from SABCS Up-to-Date Review of the Treatment of Advanced Breast Cancer

A Report from SABCS Up-to-Date Review of the Treatment of Advanced Breast Cancer. William J. Gradishar, MD Director, Breast Medical Oncology Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL.

536 views • 38 slides

Chapter 45 Antineoplastic drugs

Chapter 45 Antineoplastic drugs. Classification according to structure. Alkalyting agent Antimetabolites Antitumor antibiotics Plant alkaloids Hormonal agents Others. Classification according to mechanism of action. Drugs affecting biosynthesis of nucleic acid

944 views • 36 slides

MBC: Duration of therapy by line and subset

504 views • 35 slides

218 views • 15 slides

Breast Cancer

Breast Cancer. By Natalie Cifonie. Who is more likely to get the disease . The people that mostly get breast cancer are older women. Mostly over the age of 50. Describe symptoms . A lump in the breast or underarm Swelling in the armpit

261 views • 11 slides

Works ups

Works ups. FNAB percutaneous procedure that uses a fine gauge needle (22 or 25 gauge) and a syringe to sample fluid from a breast cyst or remove clusters of cells from a solid mass. FNAB. This type of biopsy is performed for one of two reasons:

206 views • 10 slides

Breast Cancer By: Najiyah Westry , Mikaela Dailey, and Melody Scott

Breast Cancer By: Najiyah Westry , Mikaela Dailey, and Melody Scott. Description.

216 views • 7 slides

Estrogen Receptor-Positive (ER ) Breast Cancer Pipeline Drug Profile, Top Industry Intelligence and Therapeutic Developm

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development. As per the findings of the research, a major share of ER breast cancer pipeline drug candidates are being developed to be administered by oral route. Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins. The research finds that different companies have collaborated for the development of ER breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.

82 views • 7 slides

Ewing Sarcoma Therapeutics, Clinical Trials, Results

Ewing Sarcoma Therapeutics, Clinical Trials, Results

101 views • 7 slides

ESMO 2011 Breast Cancer BOLERO-2

ESMO 2011 Breast Cancer BOLERO-2. Authors : CARE Faculty ( Drs . Anil Joy and Sunil Verma ) Date posted: October 12, 2011.

325 views • 5 slides

Promotional Response

Promotional Response. What happens when we lose focus on the main competition? FACTS: During 2000 and 2001, we talked about Femara on 61% of our calls and tamoxifen on only 56% of calls Novartis talked about tamoxifen on 76% of calls

122 views • 4 slides